894 related articles for article (PubMed ID: 30193111)
1. A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging.
Keren L; Bosse M; Marquez D; Angoshtari R; Jain S; Varma S; Yang SR; Kurian A; Van Valen D; West R; Bendall SC; Angelo M
Cell; 2018 Sep; 174(6):1373-1387.e19. PubMed ID: 30193111
[TBL] [Abstract][Full Text] [Related]
2. Multiplexed imaging analysis of the tumor-immune microenvironment reveals predictors of outcome in triple-negative breast cancer.
Patwa A; Yamashita R; Long J; Risom T; Angelo M; Keren L; Rubin DL
Commun Biol; 2021 Jul; 4(1):852. PubMed ID: 34244605
[TBL] [Abstract][Full Text] [Related]
3. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.
Bottai G; Raschioni C; Losurdo A; Di Tommaso L; Tinterri C; Torrisi R; Reis-Filho JS; Roncalli M; Sotiriou C; Santoro A; Mantovani A; Loi S; Santarpia L
Breast Cancer Res; 2016 Dec; 18(1):121. PubMed ID: 27912781
[TBL] [Abstract][Full Text] [Related]
4. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
[TBL] [Abstract][Full Text] [Related]
5. Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.
Sarradin V; Lusque A; Filleron T; Dalenc F; Franchet C
Breast Cancer Res; 2021 May; 23(1):61. PubMed ID: 34039396
[TBL] [Abstract][Full Text] [Related]
6. Modeling Multiplexed Images with
Chen Z; Soifer I; Hilton H; Keren L; Jojic V
J Comput Biol; 2020 Aug; 27(8):1204-1218. PubMed ID: 32243203
[No Abstract] [Full Text] [Related]
7. Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer.
Wei L; Wu N; Wei F; Li F; Zhang Y; Liu J; Ren X
Int Immunopharmacol; 2020 Jul; 84():106506. PubMed ID: 32330866
[TBL] [Abstract][Full Text] [Related]
8. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
9. Multiplexed ion beam imaging (MIBI) for characterization of the tumor microenvironment across tumor types.
Ptacek J; Locke D; Finck R; Cvijic ME; Li Z; Tarolli JG; Aksoy M; Sigal Y; Zhang Y; Newgren M; Finn J
Lab Invest; 2020 Aug; 100(8):1111-1123. PubMed ID: 32203152
[TBL] [Abstract][Full Text] [Related]
10. Multiplexed immunofluorescence identifies high stromal CD68
Wang J; Browne L; Slapetova I; Shang F; Lee K; Lynch J; Beretov J; Whan R; Graham PH; Millar EKA
Sci Rep; 2021 Nov; 11(1):21608. PubMed ID: 34732817
[TBL] [Abstract][Full Text] [Related]
11. Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial.
Graeser M; Feuerhake F; Gluz O; Volk V; Hauptmann M; Jozwiak K; Christgen M; Kuemmel S; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kolberg-Liedtke C; Kates R; Wuerstlein R; Nitz U; Kreipe HH; Harbeck N
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963012
[TBL] [Abstract][Full Text] [Related]
12. Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation.
Segovia-Mendoza M; Romero-Garcia S; Lemini C; Prado-Garcia H
J Immunol Res; 2021; 2021():6668573. PubMed ID: 33506060
[TBL] [Abstract][Full Text] [Related]
13. Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression.
Pinton L; Solito S; Damuzzo V; Francescato S; Pozzuoli A; Berizzi A; Mocellin S; Rossi CR; Bronte V; Mandruzzato S
Oncotarget; 2016 Jan; 7(2):1168-84. PubMed ID: 26700461
[TBL] [Abstract][Full Text] [Related]
14. PD-1/PD-L1 axis importance and tumor microenvironment immune cells.
Lotfinejad P; Kazemi T; Mokhtarzadeh A; Shanehbandi D; Jadidi Niaragh F; Safaei S; Asadi M; Baradaran B
Life Sci; 2020 Oct; 259():118297. PubMed ID: 32822718
[TBL] [Abstract][Full Text] [Related]
15. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers.
Gruosso T; Gigoux M; Manem VSK; Bertos N; Zuo D; Perlitch I; Saleh SMI; Zhao H; Souleimanova M; Johnson RM; Monette A; Ramos VM; Hallett MT; Stagg J; Lapointe R; Omeroglu A; Meterissian S; Buisseret L; Van den Eynden G; Salgado R; Guiot MC; Haibe-Kains B; Park M
J Clin Invest; 2019 Apr; 129(4):1785-1800. PubMed ID: 30753167
[TBL] [Abstract][Full Text] [Related]
16. Spatial Profile of Tumor Microenvironment in PD-L1-Negative and PD-L1-Positive Triple-Negative Breast Cancer.
Tashireva LA; Kalinchuk AY; Gerashchenko TS; Menyailo M; Khozyainova A; Denisov EV; Perelmuter VM
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674951
[TBL] [Abstract][Full Text] [Related]
17. Expression of PD-L1, indoleamine 2,3-dioxygenase and the immune microenvironment in gastric adenocarcinoma.
Patil PA; Blakely AM; Lombardo KA; Machan JT; Miner TJ; Wang LJ; Marwaha AS; Matoso A
Histopathology; 2018 Jul; 73(1):124-136. PubMed ID: 29489025
[TBL] [Abstract][Full Text] [Related]
18. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
[TBL] [Abstract][Full Text] [Related]
19. Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer.
Qiu Y; Yang Y; Yang R; Liu C; Hsu JM; Jiang Z; Sun L; Wei Y; Li CW; Yu D; Zhang J; Hung MC
Oncogene; 2021 Aug; 40(31):4992-5001. PubMed ID: 34172932
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer.
Kim JW; Nam KH; Ahn SH; Park DJ; Kim HH; Kim SH; Chang H; Lee JO; Kim YJ; Lee HS; Kim JH; Bang SM; Lee JS; Lee KW
Gastric Cancer; 2016 Jan; 19(1):42-52. PubMed ID: 25424150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
